JP2022530068A5 - - Google Patents
Info
- Publication number
- JP2022530068A5 JP2022530068A5 JP2021563064A JP2021563064A JP2022530068A5 JP 2022530068 A5 JP2022530068 A5 JP 2022530068A5 JP 2021563064 A JP2021563064 A JP 2021563064A JP 2021563064 A JP2021563064 A JP 2021563064A JP 2022530068 A5 JP2022530068 A5 JP 2022530068A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- protein
- sequence
- composition according
- replaced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1905810.6 | 2019-04-25 | ||
| GBGB1905810.6A GB201905810D0 (en) | 2019-04-25 | 2019-04-25 | Method of treatment |
| GB2000955.1 | 2020-01-22 | ||
| GBGB2000955.1A GB202000955D0 (en) | 2019-04-25 | 2020-01-22 | Method of treatment |
| PCT/EP2020/055741 WO2020216513A1 (en) | 2019-04-25 | 2020-03-04 | Method of treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022530068A JP2022530068A (ja) | 2022-06-27 |
| JP2022530068A5 true JP2022530068A5 (https=) | 2023-03-13 |
| JP7603612B2 JP7603612B2 (ja) | 2024-12-20 |
Family
ID=66810336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021563064A Active JP7603612B2 (ja) | 2019-04-25 | 2020-03-04 | 治療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220211810A1 (https=) |
| EP (1) | EP3958974A1 (https=) |
| JP (1) | JP7603612B2 (https=) |
| KR (1) | KR20220018963A (https=) |
| CN (1) | CN114072206B (https=) |
| AU (1) | AU2020263709A1 (https=) |
| CA (1) | CA3137240A1 (https=) |
| GB (2) | GB201905810D0 (https=) |
| IL (1) | IL287250A (https=) |
| WO (1) | WO2020216513A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202218084D0 (en) | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
| WO2024238859A1 (en) * | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Vectorized c5 inhibitor agents and administration thereof |
| GB202408081D0 (en) | 2024-06-06 | 2024-07-24 | Volution Immuno Pharmaceuticals Sa | Methods of removing impurities |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1629098B1 (en) | 2003-06-02 | 2009-04-01 | Varleigh Limited | Complement inhibitors from ticks |
| GB0518443D0 (en) * | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| PL2061501T3 (pl) | 2006-09-08 | 2016-01-29 | Volution Immuno Pharmaceuticals Sa | Sposób leczenia zaburzeń oddechowych |
| AU2008228247A1 (en) * | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
| SI2173890T1 (sl) * | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
| GB0802116D0 (en) * | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| GB0906779D0 (en) * | 2009-04-20 | 2009-06-03 | Natural Environment Res Council | Composition |
| JP5840623B2 (ja) | 2010-01-08 | 2016-01-06 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 気道のウイルス感染症の治療に用いるｅｖ５７６ |
| GB201401453D0 (en) * | 2014-01-28 | 2014-03-12 | Univ Birmingham | Transmucosal and transepithelial drug delivery system |
| GB201410116D0 (en) * | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| CA2988313A1 (en) | 2015-06-08 | 2016-12-15 | Volution Immuno Pharmaceuticals Sa | Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease |
| EP3359566A1 (en) * | 2015-10-07 | 2018-08-15 | Alexion Pharmaceuticals, Inc. | A method for treating age-related macular degeneration in a patient |
| SG11201811491YA (en) * | 2016-06-27 | 2019-01-30 | Achillion Pharmaceuticals Inc | Quinazoline and indole compounds to treat medical disorders |
| AU2018226872A1 (en) * | 2017-03-03 | 2019-09-05 | Macregen, Inc. | Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents |
| WO2018193120A1 (en) * | 2017-04-21 | 2018-10-25 | Volution Immuno Pharmaceuticals Sa | Coversin for the treatment of cicatrising eye inflammatory disorders |
| GB201706406D0 (en) * | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| US11730792B2 (en) * | 2017-04-21 | 2023-08-22 | Volution Immuno Pharmaceuticals Sa | Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA) |
| JP7629394B2 (ja) * | 2018-09-10 | 2025-02-13 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | リウマチ性疾患の治療に使用するためのコバーシン |
| US20220370556A1 (en) * | 2019-09-27 | 2022-11-24 | Volution Immuno Pharmaceuticals Sa | Method of Treatment |
-
2019
- 2019-04-25 GB GBGB1905810.6A patent/GB201905810D0/en not_active Ceased
-
2020
- 2020-01-22 GB GBGB2000955.1A patent/GB202000955D0/en not_active Ceased
- 2020-03-04 CA CA3137240A patent/CA3137240A1/en active Pending
- 2020-03-04 WO PCT/EP2020/055741 patent/WO2020216513A1/en not_active Ceased
- 2020-03-04 US US17/604,509 patent/US20220211810A1/en not_active Abandoned
- 2020-03-04 JP JP2021563064A patent/JP7603612B2/ja active Active
- 2020-03-04 EP EP20710849.9A patent/EP3958974A1/en not_active Withdrawn
- 2020-03-04 KR KR1020217037686A patent/KR20220018963A/ko not_active Ceased
- 2020-03-04 AU AU2020263709A patent/AU2020263709A1/en not_active Abandoned
- 2020-03-04 CN CN202080046367.0A patent/CN114072206B/zh active Active
-
2021
- 2021-10-13 IL IL287250A patent/IL287250A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6854266B2 (ja) | 抗体製剤および方法 | |
| JP2021510162A5 (https=) | ||
| JP7045333B2 (ja) | 操作されたＦｃコンストラクトに関する組成物及び方法 | |
| JP6585720B2 (ja) | 眼疾患治療のペプチド及びこれを含む眼疾患治療用組成物 | |
| JP2023040169A5 (https=) | ||
| JP2021527656A5 (https=) | ||
| JP2021533779A5 (https=) | ||
| JP2022530068A5 (https=) | ||
| JP7477457B2 (ja) | Ｃ３結合薬及びその使用方法 | |
| TW200904471A (en) | Prevention and the treatment of complement-associated eye conditions | |
| HUE032654T2 (en) | scFv antibodies that cross the epithelial and / or endothelial layers | |
| JP2021534220A5 (https=) | ||
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| JP2021511030A5 (https=) | ||
| JP2023545707A5 (https=) | ||
| KR102613962B1 (ko) | 코로나바이러스 유래 수용체 결합 도메인 및 뉴클레오캡시드 단백질을 포함하는 융합단백질 및 이의 용도 | |
| CN110156890B (zh) | Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用 | |
| WO2023001288A1 (zh) | 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用 | |
| US20240279324A1 (en) | Multispecific antagonists | |
| JP2024546129A5 (https=) | ||
| JP7606173B2 (ja) | Ｉ型インターフェロンの中和型Ｆｃ融合タンパク質及びその使用 | |
| WO2024114641A1 (en) | C5/vegf bispecific binding molecules | |
| RU2787060C1 (ru) | НУКЛЕОТИДНАЯ ПОСЛЕДОВАТЕЛЬНОСТЬ, КОДИРУЮЩАЯ СЛИТЫЙ БЕЛОК, СОСТОЯЩИЙ ИЗ РАСТВОРИМОГО ВНЕКЛЕТОЧНОГО ФРАГМЕНТА ЧЕЛОВЕЧЕСКОГО Dll4 И КОНСТАНТНОЙ ЧАСТИ ТЯЖЕЛОЙ ЦЕПИ ЧЕЛОВЕЧЕСКОГО IgG4 | |
| CN103172751B (zh) | PA4-Fc的融合蛋白及其编码基因与应用 | |
| RU2802307C2 (ru) | C3-связывающие агенты и способы их применения |